Preparing for your COVID-19 vaccination (Astra Zeneca)

If you don’t have a Medicare Number you MUST contact Services Australia  and arrange an Individual Health Identifier Number and bring it to your Appointment.  

This is to register your vaccination on the Government Register.

Please DOWNLOAD and READ the Following

Preparing for COVID-19 vaccination

COVID-19 vaccination – Information on COVID-19 AstraZeneca vaccine | Australian Government Department of Health

AstraZeneca vaccine risks versus benefits

PLEASE DOWNLOAD CONSENT FORM – PRINT and FILL IN (Bring to your Appointment)

AstraZeneca Covid-19 Vaccination Consent Form


COVID-19 Vaccine
The recommended interval between two doses of COVID-19 Vaccine AstraZeneca is 12 weeks. The minimum interval between doses is 4 weeks.
AstraZeneca progressively increased with a longer interval between doses and appeared to be greatest when the interval was ≥12 weeks.
Additional or booster doses beyond the two-dose course are not currently recommended.
There should be a minimum interval of 14 days between receipt of a COVID-19 vaccine and any other vaccine


Prophylactic use of paracetamol or ibuprofen is not recommended before receiving a COVID-19 vaccine. Antipyretics and analgesics can be taken after vaccination for management of vaccine-related side effects such as fever and myalgia, if required.


The only absolute contraindications to a COVID-19 vaccine are: ∙ anaphylaxis after a previous dose of the same vaccine ∙ anaphylaxis to any component of the vaccine, including: ∙ anaphylaxis to polyethylene glycol (PEG) for Comirnaty ∙ anaphylaxis to polysorbate 80 for COVID-19 Vaccine AstraZeneca


  • Vaccination should be deferred in people with an acute illness, including febrile illness (axillary temperature ≥38.5°C)
  • people with immediate (within 4 hours) and generalised symptoms of a possible allergic reaction (e.g. urticaria/hives) to a previous dose of a COVID-19 vaccine
  • people with a generalised allergic reaction (without anaphylaxis) to any component of the COVID-19 vaccine to be administered (e.g. PEG in Comirnaty or polysorbate 80 in COVID-19 Vaccine AstraZeneca)
  • people with a prior history of anaphylaxis to previous vaccines and/or multiple drugs (injectable and/or oral) where ingredients such as PEG or polysorbate 80 may conceivably be the cause
  • people with a known systemic mast cell activation disorder with raised mast cell tryptase that requires treatment.
  • Pregnancy

COVID-19 vaccination – COVID-19 vaccination decision guide for women who are pregnant, breastfeeding, or planning pregnancy | Australian Government Department of Health

If people in these categories are vaccinated, they may require vaccination in a facility with medical staff in attendance, and to be observed for 30 minutes following administration of a COVID-19 vaccine dose.


COVID-19 Vaccine AstraZeneca In the phase II/III trials of COVID-19 Vaccine AstraZeneca, adverse events reported within 7 days following vaccination were very common (86%) but the majority were mild or moderate.
Injection site tenderness (63.7%) and pain (54.2%) were the most commonly reported.
Fatigue (53.2%) and headache (52.6%) were the most frequently reported systemic adverse events.
Local or systemic solicited adverse events were most commonly reported on day 1 following vaccination. These reactions were generally mild to moderate and resolved within a few days. The most common systemic solicited adverse effects at day 7 were fatigue, headache and malaise. Adults aged ≥65 years reported fewer local or systemic solicited adverse events, or any ≥ grade 3 solicited adverse events than younger adults.29, 37Most adverse events did not affect daily activities. Adverse events reported after the second dose were milder and less frequent than after the first dose.

Thrombosis risk is discussed :

COVID-19 vaccination – Information on COVID-19 AstraZeneca vaccine | Australian Government Department of Health


After your COVID-19 vaccination (